During Dr. Scranton’s 30 years in the biopharmaceutical industry, he has amassed substantial drug development and executive leadership experience that coincides with multiple drug approvals and six successful company acquisitions. Most recently, Dr. Scranton served as the Senior Vice President of Late-Stage Development and Chief Operating Officer of Pfenex, Inc., a public San Diego based company.  While at Pfenex his responsibilities included oversight of numerous late-stage pre-clinical and clinical development programs, including the recently approved Bonsity (teriparatide (PTH 1-34)), before the successful transaction of Pfenex to Ligand Pharmaceutical.  Prior to Pfenex, Shawn was the Chief Scientific Officer and a member of the Sentynl Therapeutics founding executive team until it was purchased by Zydus Cadila.  Shawn also served as Senior Director of Translational Medicine for Kalypsys, Inc., where he contributed to non-clinical, clinical, and regulatory strategies for multiple NCEs focused on neuropathic pain and metabolic diseases. Formerly, Dr. Scranton was director of Clinical Development at Salmedix, Inc. (acquired by Cephalon), where Treanda (bendamustine) was developed and approved for multiple hematologic cancers.  He began his industry career as a Senior Clinical Research Scientist at Dura Pharmaceuticals after holding a joint academic position at Baylor College of Medicine and University of Houston School of Pharmacy, where he served as a Principal Investigator on numerous industry and government-supported clinical trials. Dr. Scranton earned his Doctor of Pharmacy degree from the University of the Pacific School of Pharmacy, where he also completed a two-year fellowship in cardiovascular pharmacology. He earned his bachelor’s degree in Animal Physiology from University of California, San Diego.